Seo Jeong-jin “Review of Corona 19 vaccine development… We need to secure technology sovereignty”

Celltrion Group Honorary Chairman Seo Jeong-jin revealed the possibility of developing a vaccine for Corona 19.

Honorary Chairman Seo said at an online press conference on the 18th, “Making an antibody means that you can make an antigen.” “Considering the problem of technology sovereignty of the Corona 19 vaccine, shouldn’t we have to advance into the vaccine industry?” “I’m thinking about it.”

“We are ready to make a vaccine,” he said. “It is not what the Corona 19 vaccine wants to do, but it means that when the supply to Korea is delayed, when bivalent and trivalent vaccines need to be made according to future mutations.” .

On this day, honorary chairman Seo also actively refuted the controversy over the corona 19 treatment “Recyronaju”.

Regarding the controversy over the increase in antibody-dependent infection (ADE) raised by some, the honorary chairman said, “ADE is a dengue virus phenomenon, not a corona 19 phenomenon,” and emphasized that “it has not been reported (related to Corona 19).”

Kim Seong-hyun, head of clinical planning for Celltrion, said, “It has been sufficiently proven that there are no ADE side effects that are of concern in cell and animal experiments.”

AED refers to a phenomenon in which neutralizing antibodies do not play their role and the infectivity is rather strong.

Rekironaju also entered phase 3 clinical trials with conditional approval. The global phase 3 clinical trial targets 1172 patients. Evaluate whether the incidence of severe (hospitalization, oxygen therapy) can be statistically significantly reduced.

Honorary Chairman Seo explained, “We have completed the administration to 150 patients in phase 3. We aim to finish the administration after 3 months and collect data by 5 months.”

It has also entered into development to counter the mutant virus. Celltrion plans to start developing a’customized antibody treatment’ for mutant viruses and complete the clinical trial within 6 months.

Celltrion has secured 38 neutralizing antibodies from the beginning of the development of Rekkirona, of which candidate antibody No. 32 is known to have neutralizing ability in both British and South African mutants. The neutralizing ability was also confirmed in the cocktail therapy test combined with Rekirona.

Honorary Chairman Seo said, “We have a pool of 38 neutralizing antibodies that can respond to any mutations,” and said, “We will end phase 2 clinical trials for the South African mutant virus within 6 months.”